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For many years, stem cell metabolism was viewed as a byproduct of cell fate status rather than an active
regulatory mechanism; however, there is now a growing appreciation that metabolic pathways influence
epigenetic changes associated with lineage commitment, specification, and self-renewal. Here we review
how metabolites generated during glycolytic and oxidative processes are utilized in enzymatic reactions
leading to epigenetic modifications and transcriptional regulation. We discuss how ‘‘metabolic reprogram-
ming’’ contributes to global epigenetic changes in the context of naive and primed pluripotent states, somatic
reprogramming, and hematopoietic and skeletal muscle tissue stem cells, and we discuss the implications
for regenerative medicine.Introduction
Both successful organismal development and healthy tissue
maintenance are reliant on the activity of stem cells. During
development, the earliest totipotent stem cells rapidly give rise
to the blastocyst, from which pluripotent embryonic stem cells
(ESCs) arise. These ESCs in turn commit to specific somatic
cell lineages to eventually differentiate and form the numerous
tissues and organs of the body. Importantly, in many fully differ-
entiated tissues of the adult, a subset of stem cells persists
which has often lost the ability to differentiate into more than
just a select few cell types. In contrast to the highly proliferative
state of ESCs, tissue-specific adult stem cells (ASCs) often exist
in a quiescent state (a state termed G0) and only re-enter the cell
cycle to maintain tissue homeostasis or in response to tissue
damage (Arai et al., 2004; Buczacki et al., 2013; Cheung and
Rando, 2013; Pastrana et al., 2009; Tumbar et al., 2004).
An important role for metabolism in regulating stem cell biology
derives fromstudiesdocumenting the rapidanddynamicchanges
in substrate utilization observed during early embryogenesis
(Leese, 2012). In the pre-implantation stage of mammalian devel-
opment, cellular energy in the form of adenosine triphosphate
(ATP) is generated primarily through the oxidation of carbon sour-
ces such as lactate, pyruvate, amino acids, and fatty acids, which
allow thegenerationof reducingequivalents thatdrive theelectron
transport chain (ETC) and oxidative phosphorylation (Oxphos)
(Brinster and Troike, 1979; Jansen et al., 2008; Martin and Leese,
1995). In contrast, implantation leads to a reduced oxygen avail-
ability and energy production becomes more dependent on
anaerobic glycolysis. In this latter situation, the ETC and Oxphos
become less important to satisfy energy needs (Houghton et al.,
1996; Leese, 2012; Leese and Barton, 1984). Due to the changing
environments experienced by stem cells as they progress from
pluripotency through differentiation—including oxygen and sub-
strate (carbohydrates, fatty acids, and amino acids) availability—
it is perhaps not surprising that the metabolism of ESCs differs
quite considerably from that of differentiated tissues. Similarly,ASCs often exist in specialized cellular locations termed ‘‘niches,’’
which exhibit a broad array of oxygen and substrate availabilities,
indicating that they too may differ in their metabolic state.
While the better part of the 20th century focused on the impor-
tance of cellular metabolism for the generation of energy, recent
work has uncovered an essential role for metabolism in the gener-
ationof thebuildingblocks (nucleotides,phospholipids,andamino
acids) required by rapidly dividing cells (Lunt and Vander Heiden,
2011). Additionally, the metabolite balance of both stem and
differentiated cells has been found to directly influence the epige-
nome through post-translational modifications of histones, DNA,
and transcription factors (Carey et al., 2015; Moussaieff et al.,
2015a; Ryall et al., 2015; Shiraki et al., 2014; Wellen et al., 2009).
These findings indicate that cellular metabolism is not a passive
player in the process of stem cell lineage commitment, but rather,
they suggest that changes in metabolism regulate many of the
important cell fate decisions made by stem cells. This role for
metabolism in regulating cell fate has been termed ‘‘metabolic re-
programming’’ and represents a rapidly growing field of research.
The last decade has witnessed significant advances in our un-
derstanding of the transcriptional regulation of the pluripotent
state in ESCs and the self-renewing capacity of tissue-specific
ASCs. A better understanding of the link between metabolism
and cell identity will likely lead to improvements in nuclear re-
programming (such as that used in the development of inducible
pluripotent stem cells, iPSCs), transdifferentiation, and ex vivo
expansion of stem cells for transplant therapies. In this Review,
we aim to describe the current state of knowledge regarding
stem cell metabolic reprogramming in ESCs, iPSCs, and two
types of ASCs, hematopoietic stem cells (HSCs) and skeletal
muscle stem cells (MuSCs, also termed satellite cells).
The Role of Metabolites in Epigenetic Regulation
of Transcription
From the Greek word mεtabolή (metabole), ‘‘to change,’’
metabolism defines the series of reactions necessary for theCell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc. 651
Figure 1. Cellular Metabolism and the
Production of Metabolic Cofactors for
Acetylation and Methylation Reactions
A schematic depicting the major metabolic path-
ways involved in the production of metabolites
that act as cofactors for histone deacetylation and
acetylation and histone/DNA demethylation and
methylation. Note that several intermediate steps
have been excluded for clarity.
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categorized as either oxidative (completed in the mitochondria)
or non-oxidative (completed in the cytoplasm), and it performs
at least three essential functions in stem cells: (1) the generation
of ATP necessary for energy-consuming processes; (2) the
production of glycolytic intermediates essential for anabolic re-
actions during cell division; and (3) the release of metabolites
employed in enzymatic reactions, including those involved in
mediating epigenetic modifications (Figure 1).
One of the major sources of cellular ATP is the carbohydrate
glucose. Glucose is primarily transported into the cell by a
family of specialized glucose transporters (GLUT family pro-
teins) (Mueckler and Thorens, 2013), where it undergoes a
series of reductive reactions to produce pyruvate and two
molecules of ATP (Figure 1) (Koopman et al., 2014; Lunt and
Vander Heiden, 2011). In the presence of oxygen, pyruvate
can be transported into the mitochondria by a monocarboxy-
late transporter (MCT) for Oxphos and production of a further652 Cell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc.32–36 molecules of ATP (Lin et al.,
1998). In the absence of oxygen, pyru-
vate is converted to lactate, which re-
stores the reductive power of glycolysis
by converting oxidized nicotinamide
(NAM) adenine dinucleotide (NAD+) to
reduced NAM adenine dinucleotide
(NADH). In addition to ATP, the catalytic
reactions of glycolysis provide several
intermediates that are essential for the
production of new biomass, in the form
of de novo nucleotides, phospholipids,
and amino acids (Lunt and Vander Hei-
den, 2011).
Recent progress has led to a signifi-
cant advance in our understanding
of the transcriptional networks that
regulate different stem cell states, while
improvements in genome/transcriptome
sequencing have greatly enhanced our
comprehension of the role played by
epigenetic regulators in this process.
However, work over the last several
years has identified an essential role for
metabolites in the regulation of epige-
netics and transcription, including S-ad-
enosyl methionine (SAM) produced via
the one-carbon cycle, acetyl-CoA from
glycolysis, a-ketoglutarate (aKG) and
flavin adenine dinucleotide (FAD) fromthe TCA cycle, and NAD+ from the integration of glycolysis
and Oxphos.
Glycolysis, BiomassGeneration, andProtein Acetylation
In addition to its well-documented role in generating ATP, glycol-
ysis has been found to serve several other essential roles that are
of particular relevance to the current discussion, including the
production of glycolytic intermediates necessary for the produc-
tion of new biomass and metabolites required for epigenetic
changes in transcription (Wellen et al., 2009).
The first evidence for an important role of glycolysis in cell
proliferation was provided by the seminal work of Professor Otto
Warburg (Warburg, 1956). Warburg found that highly proliferative
tumor cells preferentially utilized the glycolytic pathway, even in
the presence of saturating levels of oxygen. This process has
since been termed ‘‘aerobic glycolysis’’ or the Warburg effect.
Since Warburg’s original studies, aerobic glycolysis has been
foundtobeessential for theproductionofglycolytic intermediates,
including glucose-6-phosphate (G6P), fructose-6-phosphate
Figure 2. Metabolites as Essential Cofactors in the Epigenetic
Regulation of Transcription
(A) Acetylation of histones is achieved via the actions of histone acetyl-
transferases (HATs), which attach an acetyl group to lysine residues in a
reaction that releases co-enzyme A. In contrast, histone deactylation is
regulated via HDAC proteins, including the Sirtuin family. Sirtuins are depen-
dent on a readily available pool of NAD+ for their deacetylase activity and
produce NAM and 2’-O-Acetyl-ADP-Ribose.
(B–D) Methylation of either histone proteins or DNA is achieved via the
attachment of amethyl group (fromSAM) to either lysine or arginine residues in
a reaction mediated via HMTs (B and C) or DNMT (D). Histone demethylation
can occur via the actions of (B) the LSD family of demethylases, which require
FAD as a cofactor, or (C) the JHDM family, which require aKG as a cofactor.
The TET family of DNA demethylases similarly require aKG for their activity (D).
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of nucleotides (via the pentose phosphatase pathway, PPP).
G3P has also been found to contribute to the production of new
phospholipids, while 3-phosphoglycerate (3PG) is necessary for
the generation of the non-essential amino acids serine and glycine
(Figure 1). Lactate, previously considered to be a byproduct of
glycolysis, has also been found to contribute to anabolic and
ATP-producing processes (Sonveaux et al., 2008; Tohyama
et al., 2013).
In addition to being able to convert to lactate, pyruvate can be
transported into themitochondria where it is converted to acetyl-
CoA in a reaction catalyzed by pyruvate dehydrogenase (PDH).
The activity of PDH is inhibited following phosphorylation via
pyruvate dehydrogenase kinases (PDK1–4); thus, the glycolytic
production of acetyl-CoA is regulated both by the availability of
pyruvate and the activity of PDH and PDK enzymes (Takubo
et al., 2013). While increased PDK activity leads to a decrease
in the conversion of pyruvate to acetyl-CoA, the activity of PDK
is itself regulated via the inhibitory actions of pyruvate and
NAD+, forming a negative feedback loop between pyruvate,
PDH, and PDK (Sugden and Holness, 2003). Importantly,
acetyl-CoA can contribute to several cellular processes
including the initiation of the TCA cycle, the de novo synthesis
of lipids, and acetylation of specific amino acid residues (pre-
dominantly lysine, K) on both histone and non-histone proteins
(Figure 2A) (Koopman et al., 2014; Lunt and Vander Heiden,
2011).
Wellen and colleagues found that mammalian cells rely on
ATP citrate lyase (ACL) to convert glucose-derivedmitochondrial
citrate to nuclear acetyl-CoA, which was then found to serve as
the substrate for histone acetylation (Figure 2A). Interestingly,
while fatty acid oxidation (FAO) is also known to contribute to
the production of mitochondrial acetyl-CoA (and citrate), it
does not contribute to histone acetylation in the absence of
glucose (Wellen et al., 2009). Similar links between glycolysis
and histone acetylation have been observed in ESCs (Moussaieff
et al., 2015b), MuSCs (Ryall et al., 2015), tumor cells (Liu et al.,
2015), and yeast (Friis et al., 2009).
The removal of the acetyl group from histone proteins, termed
histone deacetylation, is regulated by a family of histone deace-
tylases (HDACs). HDACs are classified into one of four major
classes (I–IV). Class I, II, and IV include HDAC1–11 and are
Zn2+ dependent. These proteins remove the acetyl group from
histones and convert it to acetate. In contrast, class III HDAC
proteins are dependent on NAD+ for their deacetylase activity
and are known as Sirtuins (SIRT1–7). Sirtuins convert NAD+
and the acetyl group to NAM and 20-O-Acetyl-ADP-Ribose dur-
ing the process of deacetylation (Figure 2A) (Canto´ et al., 2015;
Ryall, 2012). Due to their requirement for NAD+, Sirtuins are often
thought of as energy or redox sensors. Shifts in metabolism from
aerobic to anaerobic metabolism (or vice-versa) have been
linked to changes in the NAD+/NADH ratio and Sirtuin activity.
Specifically, increased glycolysis results in decreased NAD+
availability and SIRT1-mediated deacetylation of its target his-
tone, H4 lysine 16 (H4K16) (Ryall et al., 2015). However, due to
the role of NAD+/NADH in glycolysis, the TCA cycle, andOxphos,
there is likely a complex interplay between metabolism, Sirtuins,
and histone and non-histone protein deacetylation (Do¨lle et al.,
2013; Stein and Imai, 2012).The One-Carbon Cycle and DNA/Histone Methylation
One-carbon metabolism describes a series of complex cyclical
reactions involving the transfer of a single carbon unit, and it
includes three pathways: the folate cycle, the methionine
(MET) cycle, and the trans-sulphuration cycle (Figure 1) (Loca-
sale, 2013). The combination of these cycles generates carbon
units essential for the production of phospholipids and nucleo-
tides during cell proliferation (Labuschagne et al., 2014), and
it may also regulate cellular redox status through both the oxida-
tion of NADPH and the generation of glutathione (via the trans-
sulphuration pathway).
The one-carbon cycle begins when tetrahydrofolate (THF, a
reduced form of folate) is converted to 5,10-methylene THF
(meTHF) and then reduced to 5-methyl THF (mTHF), which can
then in turn donate a carbon atom to homocysteine (hCYS) to
generate MET. The subsequent adenylation of MET leads to
the production of SAM, which functions as the methyl donor
for histone and DNA methylation reactions (Locasale, 2013).
While the most well-studied carbon donor is serine, both glycine
and threonine-derived glycine have also been found to donate a
carbon atom to initiate the cycle (Shyh-Chang et al., 2013a;
Zhang et al., 2012).
The processes of histone and DNA methylation are care-
fully regulated through the targeted actions of histoneCell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc. 653
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(DNMTs), respectively. In each case, a methyl group is trans-
ferred from SAM to a lysine or arginine amino acid, producing
S-adenosyl homocysteine (SAH) as a byproduct. SAH can then
be ‘‘recharged’’ with a methyl group via conversion to hCYS
and re-entry into the MET cycle (Figure 1, Figures 2B–2D). Inter-
estingly, acute changes in intracellular SAM can have direct ef-
fects on the level of histone methylation (particularly those asso-
ciated with active gene transcription), suggesting a dynamic role
for one-carbon metabolism in this process (Zee et al., 2010).
The mechanisms regulating the transport of metabolites
(including SAM) between intracellular compartments have yet
to be fully elucidated; however, several groups have found
that the nucleus contains key metabolic enzymes, including
those required for the conversion of MET to SAM. In a study by
Katoh et al. (2011), the SAM-generating enzyme MET adenosyl-
transferase II (MATIIa) was found to localize to the nucleus and
serve as a transcriptional corepressor of the transcription
factorMafKby interactingwith thechromatinmodifier complexes
Swi/Snf and NuRD and supplying SAM for methyltransferases.
The TCA Cycle and DNA/Histone Demethylation
Typically, mitochondrial acetyl-CoA (from glycolytic or fatty-
acid-derived acetyl-CoA) enters the TCA cycle where it un-
dergoes a process of oxidative decarboxylation to produce large
amounts of NADH and FADH2 to drive the ETC and production of
ATP (Figure 1). Several TCA and ETC intermediates are exported
out of the mitochondria and contribute to amino-acid synthesis
and epigenetic regulation of transcription via histone acetylation
(citrate) and demethylation of both DNA (aKG) and histones (aKG
and FAD).
The existence of histone demethylase proteins remained
controversial until Shi et al. (2004) identified and characterized
the actions of the protein lysine-specific demethylase 1 (LSD1,
also known as KDM1a), and found that it specifically targeted
mono- and di-methylated H3K4 and H3K9 (Shi et al., 2004,
2005). To catalyze the demethylation of its histone targets,
LSD1 has been found to require FAD, which is reduced to
FADH2 as a result of this process (Figure 2B) (Forneris et al.,
2005). Due to the close link of FAD to several metabolic pro-
cesses, this requirement of FAD for histone demethylation is
suggestive of a potential link to the metabolic status of the cell.
Intracellular FAD is produced from riboflavins (vitamin B2) and
ATP and has been found in the cytoplasm, themitochondria, and
the nucleus (Giancaspero et al., 2013). FAD is reduced to FADH2
during the conversion of acyl-CoA to 2-enoyl-CoA in FAO and
by complex II (succinate dehydrogenase) in the mitochondria.
The reverse reaction, oxidation of FADH2, occurs in the ETC,
leading to renewal of FAD and the release of two electrons.
Therefore, LSD1 demethylase activity may be dependent on
both de novo FAD synthesis from riboflavins and the relative
activity of FAO, the TCA cycle, and the ETC. Interestingly,
LSD1-mediated histone demethylation has been found to inhibit
the transcription of many key metabolic enzymes and transcrip-
tion factors, including Ppargc1a and Pdk4 (Hino et al., 2012).
These results suggest an intricate relationship between cellular
metabolism, LSD1-mediated histone demethylation, and the
transcription of metabolic regulators. Of particular relevance to
the current discussion are recent findings indicating that LSD1
can promote demethylation of H3K4me1 at the enhancer region654 Cell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc.of Oct4/Nanog/Sox target genes during ESC differentiation
(Whyte et al., 2012).
Following the initial discovery of LSD1-mediated histone de-
methylation, a second family of demethylases was identified,
with each member found to contain a characteristic Jumonji C
(JmjC) domain (Tsukada et al., 2006). The JmjC family of proteins
can target a wide range of lysine and arginine residues for deme-
thylation and, in contrast to LSD1, require aKG (and Fe2+) to
induce demethylation in an oxidative dicarboxylic reaction that
converts aKG to succinate (Figure 2C) (Tsukada et al., 2006).
The TET family of DNA demethylases similarly requires aKG
(and Fe2+) for demethylase activity (Figure 2D) (Tahiliani et al.,
2009; Yang et al., 2014). aKG is a key component of the mito-
chondrial TCA cycle. It is produced from D-isocitrate in a reac-
tion catalyzed by isocitrate dehydrogenase 2 (Idh2). In order to
be utilized by either JmjC or TET demethylation reactions, aKG
is first exported out of the mitochondria, where it can also be
converted to citrate (for the production of acetyl-CoA) or one of
several non-essential amino acids. Intracellular aKG levels are
maintained through a series of anaplerotic reactions, most
notably the breakdown of glutamine (Lunt and Vander Heiden,
2011).
Together, the above discussion strongly links metabolism and
intermediate metabolites to the processes of DNA and histone
methylation and demethylation and histone acetylation and de-
acetylation. The remainder of this discussion will focus on how
metabolism changes in stem cells and how this may deregulate
the global epigenetic signature of these cells during lineage
commitment and specification.
Metabolic Reprogramming in Pluripotent Stem Cells
Pluripotency is not an exact cell state but instead relates more to
the ability of a cell to generate the three embryonic germ layers
during development. Two broad classes of pluripotent stem cells
(PSCs) have been isolated and cultured from embryonic sour-
ces: a ‘‘naive’’ or ‘‘ground-state’’ and a ‘‘primed’’ state where
PSCs are poised to differentiate. In both cases, these cells
have been found to have a reduced mitochondrial content and
a lower inner mitochondrial membrane potential than their differ-
entiated counterparts (Prigione and Adjaye, 2010; Van Blerkom,
2009) (Figure 3A). Interestingly, naive and primed PSC states
from human and murine origins exhibit a significantly different
metabolic signature. Human embryonic stem cells (hESCs) are
frequently referred to as being in the primed state and closely
resemble pluripotent cells of the early post-implantation/epiblast
stage embryo (Nichols and Smith, 2009). Soon after hESCs were
derived, a similar primed PSC was isolated and characterized
from early-post-implantation mouse embryos, with these cells
commonly being referred to as ‘‘epiblast-like stem cells’’
(EpiSCs) (Brons et al., 2007; Tesar et al., 2007). Primed PSCs
are rather unusual in that they generate most of their ATP from
glycolysis rather than the more familiar mode of energy genera-
tion through Oxphos as observed in naive PSCs (Figure 3A)
(Varum et al., 2011).
Primed PSCs Rely on Glycolysis
Elevated rates of extracellular acidification (ECAR, a measure of
glycolysis) and lactate production and excretion are hallmarks of
human andmurine primed PSCs undergoing rapid glycolytic flux
(Figure 3A) (Varum et al., 2011; Zhou et al., 2012). Even though
Figure 3. Stem Cell Metabolism during
Lineage Commitment and Reprogramming
This diagram attempts to collate our current
knowledge regarding metabolism and the pro-
cesses of lineage commitment and reprogram-
ming in (A) ESCs and (B) ASCs (using MuSCs as
an example). The position of each cell type is
correct relative to its nearest neighbor; however,
the position of reprogrammed pluripotency is
speculative.
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ygen is consumed and respiratory complexes in the mitochon-
dria are fully active and serve to maintain membrane potential
across the inner membrane (Zhang et al., 2011). Oxygen con-
sumption, however, is uncoupled from ATP generation in this
scenario presumably due to low expression of the ETC complex
V subunit cytochrome C oxidase (COX) (Zhang et al., 2011). Dif-
ferences in the expression of COX genes in mouse were
confirmed by the comparison of transcript levels across the
blastocyst-to-epiblast transition in vivo (Zhang et al., 2011), indi-
cating that the metabolic switch described occurs in normal
development. ATP is primarily generated from glycolysis to fuel
the cell, with little contribution from the reducing equivalents
generated by the TCA cycle. Other consequences of a glycol-
ysis-based energy-generating system include an increase in
flux through the PPP to drive ribose production for nucleotide
generation, along with the synthesis of enzymatic cofactors
coenzyme A and NAD+/NADH (Figure 1). During the reprogram-
ming of human cells to iPSCs, increased glycolytic activity oc-
curs prior to the establishment of iPSCs, perhaps suggesting
that altered metabolism is a prerequisite for establishment of
primed pluripotency (Figure 3B) (Hansson et al., 2012; Kida
et al., 2015; Panopoulos et al., 2012; Shyh-Chang and Daley,
2013). The utilization of glycolysis as a prime means to generate
ATP is reminiscent of the Warburg effect, originally described in
tumor cells.
The majority of mammalian cells (including primed PSCs)
require glutamine for proliferation as a source of nitrogen and
anaplerosis (the maintenance of TCA cycle intermediates). In
primed PSCs the absence of glutamine has been found to lead
to depleted aKG levels, which in turn reduces the activity of his-
tone demethylases and results in increased H3K9, H3K27,
H3K36, andH4K20 trimethylation and subsequent differentiation
(Carey et al., 2015). Interestingly, results from the same study
showed that naive PSCs could proliferate and maintain histone
demethylation in the absence of glutamine through the utilization
of glucose to maintain aKG levels (Figure 1) (Carey et al., 2015).
The most frequent argument to explain why primed PSCs use
glycolysis and not Oxphos is that the early post-implantation-
stage embryo is not vascularized by capillaries and grows at a
rapid rate in a low-oxygen environment. Although this is a logical
assertion, there are several aspects of this metabolic program
that do not seem very efficient. For example, why dispose of
large quantities of carbon skeleton in the form of lactate? Lactate
secretion may provide some form of beneficial effect and mayserve as a carbon source for surrounding cells that support
development of the embryo. The rate at which glycolysis pro-
duces pyruvate may exceed the rate at which it can be further
oxidized through the TCA cycle; the resulting excess can be
eliminated from the cell by its conversion and secretion as
lactate. Additionally, the conversation of pyruvate to lactate
can recycle the NADH generated by GAPDH in glycolysis back
to NAD+, allowing the cell to modulate its NAD+/NADH ratio
and thus Sirtuin-mediated histone deacetylation. Production of
lactate could therefore be an unnecessary consequence of
elevated glycolytic flux. Uncoupling Oxphos from energy pro-
duction also reduces the accumulation of reactive oxygen spe-
cies (ROS) that have genotoxic effects. It is obviously beneficial
to limit ROS levels in stem cell populations so as to maintain
genomic integrity (Suda et al., 2011). Primed PSCs are now
frequently cultured under reduced oxygen conditions (2%) as
this has been reported to suppresses spontaneous differentia-
tion (Ezashi et al., 2005).
Naive PSCs Predominantly Utilize Oxphos
The naive PSC state represents an earlier stage of pluripotency
than primed cells, and these cells more closely resemble
PSCs of the inner cell mass (ICM). For the purpose of this discus-
sion, murine ESCs (mESCs) cultured under traditional conditions
with leukemia inhibitory factor (LIF) and fetal calf serum (FCS) will
be considered alongside ground-state cells as they more closely
resemble ICM-derivedPSCs.Unlike primedPSCs, naive cells are
less reliant on glycolysis for energy generation, release less
lactate, and utilize Oxphos for energy generation (Figure 3A)
(Takashima et al., 2014; Zhou et al., 2012). This metabolic switch
coincideswith increased COXgene activity and an overall recon-
figuration of mitochondrial activity. In the preceding discussion,
reasons were posed to explain why primed PSCs use primarily
glycolysis for their energetic needs. Although the rationale used
to argue that glycolysis-based metabolism is beneficial for
primed PSCs is sound, it is unclear why the same factors do
not seem necessary for naive cells where genomic integrity is
equally important. Cell multiplication rates are comparable
so biomass considerations are unlikely to be the explanation.
So too is the argument that glycolysis supports anabolic
metabolism. Reports that oxygen consumption in primed cells
remains elevated is surprising as oxygen tension would be a po-
tential cause. The rationale for why naive and primedPSCs utilize
a remarkably different mode of metabolism is therefore unclear.
Dramatic changes in metabolic patterns emphasize the
concept that metabolism is developmentally regulated and hasCell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc. 655
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embryogenesis. It will be interesting then to determine how
changes in metabolic pathways are regulated and to establish
how they are hard-wired into developmental programs. One
interesting possibility is that differing enzymatic isoforms, which
utilize different reaction rates, substrate affinities, and modes of
regulation, can alter metabolic modes and are regulated at the
transcriptional level by developmental transcription factors that
orchestrate cell fate decisions.
Shiraki and colleagues (2014) have reported that hPSCs
consume MET at elevated levels relative to their differentiated
counterparts. When MET is depleted from media, cells undergo
increased rates of apoptosis and sporadic differentiation.
Elevated MET fluxes increase levels of SAM that impact the
epigenetic status of a cell (Figure 1). For example, SAM seems
to be required for maintenance of normal H3K4 trimethylation
and DNA methylation in hPSCs (Shiraki et al., 2014). MET depri-
vation is rescued by SAM supplementation, indicating that
MET’s critical role is in epigenetic regulation.Whether this is spe-
cifically part of a PSC program is unclear, however, as these
pathways are clearly important in other cell types.
Similarly to hESCs, SAM appears critical for the maintenance
of pluripotency in mESCs. However, in contrast to humans, mice
have an active copy of the gene encoding threonine dehydroge-
nase (Tdh) and rely more heavily on threonine as themain source
of SAM (Shyh-Chang and Daley, 2013). The availability of key
amino acids therefore seems to be an important factor in deter-
mining the epigenetic state in PSCs. Other examples include
L-proline, which destabilizes self-renewing mESCs and pro-
motes differentiation (Washington et al., 2010). In this case, the
L-proline-induced transition of mESCs to a mesenchymal state
is linked to changes in H3K36me2 and H3K9me3 status (Comes
et al., 2013). Moreover, ascorbate has been implicated as a
cofactor in epigenetic regulation of mESCs by regulating JmjC
histone demethylation enzymes (Wang et al., 2011; Young
et al., 2015) and TET enzymes (Blaschke et al., 2013; Gao
et al., 2013; Minor et al., 2013) that catalyze the conversion of
5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC).
Regulation of histone acetylation by cytoplasmic acetyl-CoA
also seems to be an important determinant of the PSC state.
High glycolytic rates drive this process and have recently been
shown to be critical for stem cell maintenance (Moussaieff
et al., 2015a). Consistent with this, glycolytic rates, acetyl-CoA
levels, and global histone acetylation decline during early differ-
entiation.
Modulation of intracellular O-GlcNAc levels also appears to be
important in PSCs. O-GlcNAc is a carbohydrate modification
primarily associated with post-translational modification of intra-
cellular proteins on serine and threonine residues and is pro-
posed to function as a nutrient sensor. O-GlcNAc impacts a
wide range of targets that affect epigenetic status, including his-
tones, RNA polymerase II, and histone deacetylases, and seems
to be a key point of regulation that links nutritional status to gene
regulation and cell identity (Hanover et al., 2012). One particularly
interesting role of O-GlcNAc modification is its impact on DNA
methylation inmESCs. Here, the TET1 and TET2 enzymes, which
convert 5-mC to 5-hmC, are activated byO-GlcNAcmodification
in mESCs (Shi et al., 2013; Vella et al., 2013). In this context,
O-GlcNacylation of TET1 would demethylate target genes,656 Cell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc.thereby contributing to the pluripotent state perhaps by regu-
lating CpG islands. The key metabolic regulator and oncogene
MYC is another target of O-GlcNAc transferase (OGT) (Chou
et al., 1995). MYC is especially interesting in the context of
stem cell biology because it is awell-established regulator of plu-
ripotency and self-renewal (Cartwright et al., 2005; Smith et al.,
2010). Other members of the core pluripotency network such
as Oct4 and Sox2 are also OGT-modified in PSCs (Jang et al.,
2012). Mutation of OCT4 that prevents it from being modified
by OGT reduces the functionality of Oct4 including its ability to
sustain pluripotency. Presumably, high glycolytic fluxes in
PSCsmaintain O-GlcNAc availability and support the pluripotent
state by targeting critical epigenetic modifiers.
Metabolism, Pluripotency, and Reprogramming
Increasing evidence linking glycolytic metabolism and pluripo-
tency raises a question about the role of metabolism during nu-
clear reprogramming. Small molecule activators of glycolysis
and inhibitors of Oxphos have been shown to increase reprog-
raming efficiencies with the Yamanaka factors; correspondingly,
inhibition of glycolysis through small molecules greatly dimin-
ishes reprogramming abilities (Folmes et al., 2011; Prigione
et al., 2014; Zhu et al., 2010). Research into the understanding
of the minimal requirements for cellular reprograming has led
to the identification of metabolic modulators as MYC targets. It
has been shown that manyMYC targets lie outside the canonical
Oct4/Sox2/Nanog regulatory network (Cao et al., 2015; Chen
et al., 2008; Kim et al., 2008; Ng and Surani, 2011). MYC, as
with the other Yamanaka factors, has been shown to be replace-
able in numerous reprograming protocols when these replace-
ments are metabolic modulators (Chen et al., 2011; Li et al.,
2005; Shyh-Chang and Daley, 2013). For example, inactivation
of mTOR via rapamycin or other compounds induces glycolytic
gene expression during reprograming in the absence of MYC
(Chen et al., 2011; Zhu et al., 2010). Modulation of miRNAs,
such as miR-290/371 and the lin28/let-7 pathway, which pro-
motes glycolytic gene expression, can also be used to replace
MYC as a reprograming factor (Cao et al., 2015; Shyh-Chang
and Daley, 2013). Induced expression of key metabolic enzymes
(Ldha and Pkm2) can also replaceMYC as reprograming factors,
while their repression blocks iPSC formation (Cao et al., 2015).
Finally, upregulation of genes associated with a glycolytic-based
metabolism occurs before expression of pluripotency genes
during iPSC formation (Cao et al., 2015; Folmes et al., 2011;
Prigione et al., 2014; Zhu et al., 2010).
Recently, Kida and colleagues have investigated the meta-
bolic changes that occur during the establishment of pluripo-
tency in iPSCs (Kida et al., 2015). In this study, the authors
identified the estrogen-related nuclear receptor (ERRa and
ERRg), PGC1a, and PGC1b as key switches in the regulation
of Oxphos during early iPSC reprogramming and demonstrated
a significant increase in both oxygen consumption and extracel-
lular acidification (an indirect measure of glycolysis) during the
first 3–4 days of reprogramming in mouse embryonic fibroblasts
(MEFs, Figure 3B). This ‘‘metabolic burst’’ was then followed
by a significant decrease in oxygen consumption and a further
increase in extracellular acidification such that successfully
reprogrammed iPSCs had a 2-fold increase in extracellular acid-
ification compared to the MEF cells from which they were
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cellular metabolism occurred during a period marked by minimal
changes in gene expression (Polo et al., 2012), suggesting that
metabolic reprogramming is a prerequisite for successful induc-
tion of pluripotency. Further evidence for a link between meta-
bolism and reprogramming efficiency is provided by a recent
study demonstrating that the oocyte-enriched factor Tcl1
improved iPSC reprogramming efficiency by suppressing the
mitochondrial polynucleotide phosphorylase (PnPase). By pre-
venting the mitochondrial localization of PnPases, Tcl1 inhibited
mitochondrial biogenesis and oxygen consumption and elevated
the ECAR. Interestingly, these changes were associated with an
enrichment of several glycolytic intermediates, including fruc-
tose 1,6-biphosphate and phosphoenolpyruvate (Khaw et al.,
2015).
Metabolic Reprogramming in ASCs
Many bodily tissues and organs have been found to contain their
own population of stem cells, with examples including hemato-
poietic, neural, stomach (crypt), intestine, and MuSCs. In
contrast to the pluripotent state exhibited by ESCs, many
ASCs are tissue-specific and capable of asymmetric division
leading to a committed daughter cell and a stem cell for self-
renewal (Goulas et al., 2012; Kuang et al., 2007; Rocheteau
et al., 2012; Troy et al., 2012; Zimdahl et al., 2014).
Tissue-specific stem cells have been found to vary dramati-
cally in their turnover rates, with some populations undergoing
constant cell division and others existing in a quiescent state
outside of the cell cycle, only undergoing cell division in response
to tissue damage. In addition, the local niche environment of
ASCs can vary in substrate and oxygen availability and pH,
among other parameters. There is currently a dearth of knowl-
edge regarding the metabolic status of these tissue-specific
stem cell populations and how the local metabolic milieu may
act to regulate aspects of stem cell biology. Of particular interest
is themetabolic status of those stem cell populations that exist in
a quiescent state, such as adult HSCs and MuSCs. While an
increased reliance on glycolysis appears common for most
ASC populations during phases of proliferation, the metabolic
status of quiescence is only just beginning to receive attention.
HSCs
HSCs are typically found in a quiescent state in bone marrow, a
location originally believed to be highly anaerobic (Passegue´
et al., 2005; Simsek et al., 2010; Suda et al., 2011). Computa-
tional modeling based on data obtained by BrdU and histone
H2B-GFP label-retaining assays suggests that a population of
dormant mouse HSCs (d-HSCs) divides every 149–153 days
and harbors the vast majority of multilineage, long-term self-re-
newing cells induced by hematopoietic stress. This population
of HSCs is poised for rapid entry into the cell cycle in response
to an emergency situation (e.g., significant blood loss) and gives
rise to all hematological progenitors including red blood cells,
granulocytes, platelets, T cells, and B cells. A second, active
HSC (a-HSC) subset generates the progenitors and mature cells
involved in the day-to-day maintenance of hematopoietic ho-
meostasis and cycles every 28–36 days (Foudi et al., 2009; van
der Wath et al., 2009; Wilson et al., 2008).
Recent studies have shown that quiescent HSCs specifically
associate with rare pericytes (NG2+ cells) and that activation ofthe HSC cell cycle alters the distribution of HSCs fromNG2+ peri-
arteriolar niches to leptin-receptor-positive (LEPR+) perisinusoi-
dal niches. Moreover, depletion of NG2+ cells induces HSC
cycling and impairs long-term HSC repopulation in the bone
marrow (Kunisaki et al., 2013). Despite bone marrow being a
highly vascularized tissue, two-photon microscopy has revealed
that the absolute local oxygen tension of the bone marrow is
quite low (<32 mm Hg). Interestingly, the lowest oxygen tension
(9.9 mm Hg) is detected in deeper perisinusoidal regions
whereas the endosteal region is less hypoxic (Spencer et al.,
2014). It will be of interest to determine whether these low-oxy-
gen-tension perisinusoidal regions correspond to the LEPR+
perisinusoidal niches and whether decreased oxygen tension
is sufficient to induce HSC activation.
The hypoxic niche hypothesis for the maintenance of quies-
cence in HSCs is, in part, supported by findings that the tran-
scription factor hypoxia-inducible factor 1a (HIF1a) is stabilized
within these cells (Takubo et al., 2010). HIF1a can form hetero-
dimers with the constitutively expressed HIF1b and induce
transcription of several genes, including key glycolytic enzymes.
The depletion of HIF1a has been found to coax HSCs toward a
more oxidative metabolism and leads to depletion of the HSC
pool (Takubo et al., 2013). While the importance of HIF1a in the
maintenance of HSCs is clear, its stabilization can occur through
hypoxia independent mechanisms (Lu et al., 2002), so its activity
alone cannot be used to define HSC metabolism. The vast ma-
jority of studies have proposed that quiescent HSCs rely on
anaerobic glycolysis, a result supported by findings of elevated
levels of PKM2 and PDK1–4. However, Nombela-Arrieta et al.
(2013) have employed laser scanning cytometry to demonstrate
that the bone marrow niche has an extensive vascular network,
and Takubo et al. (2013) have used a Seahorse XF Bioanalyzer
to demonstrate that quiescent HSCs still consume oxygen
(50% of that consumed by actively proliferating HSCs). These
results suggest that despite the PDK-mediated inhibition of the
conversion of pyruvate to acetyl-CoA, the TCA cycle and ETC
remain active in quiescent HSCs. One possible explanation for
these discrepant results is a reliance on FAO, which circumvents
the need for glucose-derived acetyl-CoA. Clearly, the roles of
vascularization and oxygen tension in the regulation of HSC
biology remain a fertile and controversial area of investigation.
Long-term HSCs (LT-HSCs) contain fewer mitochondria than
more committed progenitors, in terms of both mitotracker incor-
poration (Simsek et al., 2010) and morphology (Kim et al., 1998),
and utilize glycolysis instead of Oxphos via a transcriptional reg-
ulatory network comprising Meis1 and HIF1a (Simsek et al.,
2010). Takubo and colleagues have published a metabolic pro-
file of glycolytic metabolism in HSCs and their progenitors,
with the results suggesting an elevated level of several important
metabolites in HSCs, including F1, 6BP, and pyruvate (Takubo
et al., 2013). Interestingly, several TCA cycle intermediates
were present at detectable levels in all cells examined, suggest-
ing that while glycolysis may predominate in HSCs, the mito-
chondria remains active in these cells (Takubo et al., 2013).
Similarly to ESCs, the reliance of quiescent HSCs on glycolysis
has been proposed as a method to minimize the buildup of
damaging ROS (Suda et al., 2011). Utilizing conditional deletion
strategies in mice, Wang and colleagues have found that PKM2
plays an important role in the inhibition of Oxphos activity andCell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc. 657
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LDHA is essential for HSC self-renewal (Wang et al., 2014). As
LDHA plays an important role in the regeneration of NAD+ to
allow glycolysis to proceed, it is possible that SIRT1 deacetylase
activity is altered under these conditions. Indeed, SIRT1 activity
has previously been linked to the maintenance of the HSC pool
(Rimmele´ et al., 2014). However, whether this is related to the
changing metabolic state of HSCs awaits further investigation.
An additional mechanism important for the inhibition of Ox-
phos activity in quiescent HSCs is the elevated expression of
PDK1–4. Takubo et al. have demonstrated that increased PDK
activity is essential to prevent conversion of glucose-derived py-
ruvate to acetyl-CoA in the mitochondria and that PDK activity is
directly linked to the self-renewal capacity of HSCs (Takubo
et al., 2013). In this study, the authors isolated HSCs from
PDK2/PDK4/ double knockout mice and found that they
had a reduced capacity to successfully repopulate an irradiated
recipient mouse. Furthermore, HSCs from PDK2/PDK4/
mice exhibited increased Oxphos activity and expression of
the senescent marker p16 (Takubo et al., 2013). These results
differ from those obtained in a more recent study where ESCs
cultured in the presence of dichloroacetic acid (DCA, an inhibitor
of PDKs) were better able to maintain pluripotency (Moussaieff
et al., 2015a). Thus, the process of metabolic reprogramming
is likely different in different populations of stem cells.
Ito et al. (2012) have identified an essential role for FAO in the
maintenance of quiescence and self-renewal in HSCs. In this
study the authors found that treatment of quiescent HSCs with
the FAO inhibitor etomoxir led to an initial expansion of cell
numbers (suggestive of an exit from quiescence), followed by
an exhaustion of the HSC pool. These authors also found that
targeted deletion ofPpard (a transcription factor intricately linked
to the process of FAO) in HSCs led to precocious exit from quies-
cence (Ito et al., 2012). Therefore, it is essential that future
studies investigate the role of FAO-derived acetyl-CoA and
Oxphos in the maintenance of the HSC pool, particularly as
acetyl-CoA has been linked to pluripotency in ESCs (Moussaieff
et al., 2015a).
Many of the enzymes regulating DNA methylation and histone
modifications described in the preceding paragraphs have
important functions in HSC maintenance and differentiation
(Cullen et al., 2014), thus suggesting an intertwined role of meta-
bolism and epigenetics in HSCs biology.
MuSCs
MuSCs sustain early post-natal muscle growth and are respon-
sible for the high regenerative capacity of skeletal muscle in
response to trauma or injury and during the compensatory
phases of muscle degeneration characteristic of several muscle
dystrophies (Brack and Rando, 2012; Ryall, 2013; Yin et al.,
2013). Like HSCs, MuSCs exist in a quiescent state; however,
the rate of cellular turnover is significantly less in MuSCs, with
a recent study estimating the average age of nuclei in human
adult muscle to be >15 years (Spalding et al., 2005). Further-
more, while HSCs are poised for activation, the process of
MuSC activation (measured as the time to first division) has
been found to be upward of 30 hr (Rocheteau et al., 2012; Rodg-
ers et al., 2014). Based on H2B-GFP intensity, at least twoMuSC
populations have been identified: MuSCs retaining (LRC) or
losing (nonLRC) the H2B-GFP label. Both LRCs and nonLRCs658 Cell Stem Cell 17, December 3, 2015 ª2015 Elsevier Inc.are formed at birth and remain during post-natal growth and
adult muscle repair. Adult LRCs give rise to both LRCs and
nonLRCs, with the former self-renewing and the latter dedicated
to differentiation (Chakkalakal et al., 2012, 2014). MuSC LRCs
may be the equivalent of d-HSCs, whereas the behavior of
MuSC nonLRCs is reminiscent of that of a-HSCs. Similar to
HSCs, quiescent MuSCs have been found to closely colocalize
with capillaries, suggestive of an aerobic niche (Christov et al.,
2007; Ryall, 2013). Interestingly, skeletal muscles that exhibit
greater capillarization (so called ‘‘oxidative’’ or ‘‘slow-twitch’’
muscles) have also been observed to contain a higher density
of MuSCs (Christov et al., 2007). Thus, while both quiescent
HSCs and MuSCs are located in close proximity of vasculature,
the actual local oxygen tension to which these cells are exposed
can change depending on their anatomical location (perisinusoi-
dal versus endosteal regions for HSCs). The local oxygen tension
of quiescent MuSCs remains to be determined.
By combining lineage-tracing models and fluorescence-
activated cell sorting (FACS), several authors have identified a
process of mitochondrial biogenesis during the shift from quies-
cence to proliferation of MuSCs (Rocheteau et al., 2012; Rodg-
ers et al., 2014). Despite mitochondrial biogenesis having been
observed to increase in activated MuSCs (Ryall et al., 2015;
Tang and Rando, 2014), the rate of oxygen consumption does
not seem to change between quiescent, early (3 hr in growthme-
dia), and late (20 hr in growth media) cultured activated MuSCs,
with the rate of glycolysis increasing 3-fold within the first 3 hr
of activation (Figure 3B) (Ryall et al., 2015). These results match
the metabolic gene signature obtained via RNA sequencing and
microarray, with an enrichment of FAO genes in quiescent
MuSCs and glycolytic genes in activated MuSCs (Liu et al.,
2013; Pallafacchina et al., 2010; Ryall et al., 2015). This increase
in glycolysis is likely a result of the augmented demand for glyco-
lytic intermediates essential for the generation of new biomass
required by dividing cells (Lunt and Vander Heiden, 2011). The
lack of increase in oxygen consumption in activated MuSCs,
despite mitochondrial biogenesis, is reminiscent of that
observed during the shift from the naive/ground-state of ESCs
to the primed state of EpiSCs (Varum et al., 2011). Whether the
mechanisms underlying this disconnect between mitochondrial
density and oxygen consumption are similar between ESCs
and MuSCs deserves further investigation.
The metabolic signature of quiescent MuSCs is linked to an
elevated NAD+/NADH ratio and high activity of the deacetylase
Sirtuin SIRT1 (as inferred by low acetylation levels of the SIRT1
target histone H4 lysine 16, H4K16ac) (Ryall et al., 2015). In
contrast, the increase in glycolysis observed in activated MuSCs
was linked to a decrease in the NAD+/NADH ratio and a reduc-
tion in SIRT1 deacetylase activity (10- to 20-fold increase in
H4K16ac). Importantly, these changes in histone acetylation
were linked to the transcription of several important myogenic
regulatory genes (Ryall et al., 2015). These results provide an
example of how metabolic modifications can be linked, via epi-
genetics, to changes in transcription and stem cell state.
Several groups have identified changes in both global and
site-specific histone methylation as MuSCs leave quiescence
and enter the cell cycle and again during differentiation (Juan
et al., 2011; Liu et al., 2013). Liu and colleagues have previously
used freshly isolated and cultured single muscle fibers to
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H3K4me3. Further analysis of site-specific H3K4me3 enrich-
ment using chromatin-immunoprecipitation sequencing (ChIP-
seq) demonstrated that the number of genes marked by
H3K4me3 did not change following MuSC activation (Liu et al.,
2013). In contrast, both global and site-specific H3K27me3
have been found to be enriched following MuSC activation, likely
a result of elevated levels of the HMT Ezh2 and a reduction in the
expression of the histone demthylase Jmjd3 (Juan et al., 2011;
Liu et al., 2013). What role the one-carbon cycle and FAD/aKG
availability may play in these changes has yet to be investigated.
However, it is interesting to note that several genes encoding key
serine biosynthesis enzymes (Phgdh, Psat1, and Psph) are >10-
fold elevated following MuSC activation, suggesting a possible
link to histone/DNA methylation (see the supplemental RNa-
seq andmicroarray data files in Liu et al., 2013; Ryall et al., 2015).
In addition to stem cells utilizing available substrates, recent
work has suggested that MuSCs (and indeed other stem cell
populations) may use protein degradation as a novel method to
generate new substrates. The autophagic pathway, leading to
protein degradation, is typically associatedwith themaintenance
of homeostasis due to its role in removal of damagedormisfolded
proteins (Das et al., 2012). However, autophagy has recently
been found to play an important role in stem cell biology. Tang
andRando (2014) have found that the processes ofMuSCactiva-
tion and proliferation are associated with an increase in
autophagic activity. While this increase may be due to the
bioenergetic demand for ATP, it is interesting to postulate an
additional role for autophagy in the production of metabolites
essential for the extensive chromatin remodeling that occurs dur-
ing MuSC activation and specification (Tang and Rando, 2014).
Therapeutic Potential of Stem Cell Metabolic
Reprogramming
The results presented in this discussion link metabolism to
changes in the epigenetic state of both embryonic cells and
ASCs. Accordingly, several groups have now demonstrated
the efficacy of using targeted metabolic reprogramming strate-
gies to improve nuclear reprogramming or tissue repair following
injury (Shyh-Chang et al., 2013b; Zhu et al., 2010). In one such
study Shyh-Chang and colleagues have shown that topical
application of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG)
improves the rate of ear regeneration following pinnal injury;
interestingly, this response was associated with an acute
decrease in the NADH/NAD ratio (Shyh-Chang et al., 2013b).
While this Review has focused on the ability of metabolism
to regulate transcription, it is also important to recognize that
transcription factors, RNA-binding proteins, and chromatin re-
modeling machineries involved in either cell reprogramming or
influencing cell fate determination also exert profound effects
on the metabolic state. Small molecules modulating metabolic
pathways and transcriptional outcomes influence stem cell fate
and function (Li et al., 2013), and corrected PSCs from patients
with mitochondrial DNA mutations display normal metabolic
function compared to mutant cells (Ma et al., 2015).
Conclusions
In this Reviewwe have presented an extensive discussion of how
metabolism and substrate utilization can regulate transcriptionvia metabolites acting as cofactors for epigenetic regulators. In
addition, we have described the current state of knowledge
regarding the changes in metabolism that occur during stem
cell specification, differentiation, and reprogramming. However,
it is our hope that this Review has also highlighted the gaps in our
understanding of the process of metabolic reprogramming in
stem cells. Future studies investigating epigenetic changes in
stem cell populations will likely include analyses of intracellular
metabolites and cellular metabolism, as an increased under-
standing of the process of metabolic reprogramming in stem
cells will lead to significant advances in the fields of stem cell
transplantation and regenerative medicine.ACKNOWLEDGMENTS
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